NSP-5033

NSP-5033: sourced facts only. name: "Herein, we describe the discovery of a novel small molecule NSP-5033 as a dual PARP7/PARP12 inhibitor, which potently inhibits PARP7 and PARP12 enzymes with sub-nanomolar and low nanomolar activities, respectively." [DOI:10.1158/1538-7445.am2024-7588]; target: "Herein, we describe the discovery of a novel small molecule NSP-5033 as a dual PARP7/PARP12 inhibitor, which potently inhibits PARP7 and PARP12 enzymes with sub-nanomolar and low nanomolar activities, respectively." [DOI:10.1158/1538-7445.am2024-7588]; developer: "1Novostar Pharmaceuticals, Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2024-7588]; modality: "Herein, we describe the discovery of a novel small molecule NSP-5033 as a dual PARP7/PARP12 inhibitor, which potently inhibits PARP7 and PARP12 enzymes with sub-nanomolar and low nanomolar activities, respectively." [DOI:10.1158/1538-7445.am2024-7588]; stage: "With excellent ADME and pharmacokinetic properties, NSP-5033 demonstrated potent in vivo efficacy in human lung cancer xenografts with tumor regression and induced antitumor immunity in tumor-bearing immunocompetent mice." [DOI:10.1158/1538-7445.am2024-7588]